Similar to commercially available bi-specific antibodies in lymphoid malignancies, these NK cell engagers are able to concurrently bind both tumor antigens and NK cell receptors, thereby facilitating recruitment and cytotoxicity. The gene discussed is KLRD1; the disease is neoplasm.